Abstract
ALTHOUGH it has long been known that the rare-earth metals interfere with blood clotting both in vitro and in vivo, it was not until 1950 that Vincke and Sucker1 described, in neodymium 3-sulpho-isonicotinate, a compound that was sufficiently soluble and free of toxic effects for clinical use. It is given by intravenous injection in 2.5 per cent solution and was at first regarded as a prothrombinopenic agent on the basis of a prolonged one-stage ‘prothrombin’ time. Recently, using newer techniques, Beller and Mammen2 have reported that neodymium acts by reducing factor VII and factor X, leaving prothrombin normal. We have meantime been studying, independently, the mode of action of this salt, using in particular the blood thromboplastin generation test3, with the following results.
Similar content being viewed by others
Article PDF
References
Vincke, E., and Sucker, E., Klin. Wschnschr., 28, 74 (1950).
Beller, F. K., and Mammen, E., Arch. für Gynäkologie, 187, 319 (1956).
Biggs, R., and Douglas, A. S., J. Clin. Path., 6, 1, 23 (1953).
Walker, W., and Hunter, R. B., Nature, 173, 1192 (1954).
Koller, F., communication to European Congress of Hæmatology, Amsterdam (1953).
Bergsagel, D. E., Brit. J. Hæmat., 1, 2, 199 (1955).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
HUNTER, R., WALKER, W. Anticoagulant Action of Neodymium 3-Sulpho-isonicotinate. Nature 178, 47 (1956). https://doi.org/10.1038/178047a0
Issue Date:
DOI: https://doi.org/10.1038/178047a0
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.